Value
6.1/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 1.7 |
| Analyst target | 9.0 |
ARCT · Why this verdict
Why Arcturus Therapeutics Holdings (ARCT) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score4.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
ARCT is a loss-making biotech with collapsing revenue ($29.4M to $3.0M in the last year-over-year comparison) and a $370M market cap that keeps it outside the investable universe, though it has beaten EPS estimates in 3 of the last 4 quarters and sits 54.9% below its analyst target.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Quarterly revenue fell from $29.4M (March 2025) to $2.1M (March 2026) and $3.0M (June 2026), while net margin, ROE and ROA all score 0.0. Revenue quarters | Quarterly revenue should recover toward the $8.0M next-quarter estimate over the next 12 months. | ↓Deteriorating |
| CounterCollaboration revenue is milestone-based and lumpy, and revenue data shows large divergence between XBRL and yfinance (70% for the latest quarter), so the trend may be mismeasured. | ||
Market cap $370M below $400M minimum keeps the stock outside the investable universe regardless of other scores. Bear case | Market cap should rise above $400M for the stock to rejoin the investable universe. | ↓Deteriorating |
| CounterThe shortfall is only $30M, about 8%, so a modest price rise would qualify the stock; the screen threshold may be more arbitrary than informative. | ||
High short interest of 24% and an elevated put/call ratio of 30.25 show strong bearish positioning against the stock. Key risks | Short interest should fall below 15% and put/call ratio should normalize if sentiment improves. | ↓Deteriorating |
| CounterThe engine notes the high short interest is justified, but heavily crowded shorts can also fuel a squeeze on any positive trial news. | ||
Strong earnings: 3B/1M, with the latest quarter at EPS of -0.84 versus a -1.03 estimate (+18.1% surprise), showing losses narrower than analysts expect. Catalyst breakdown | EPS should beat estimates again at the 2026-11-09 report, keeping the beat count at 3 of the last 4 or better. | ↓Deteriorating |
| CounterBeating a loss estimate is not profitability; the company still loses roughly $0.84 per share each quarter, and one miss (-36.4%) was large. | ||
After a 46% drawdown from the 52-week high, the stock trades 54.9% below its $20.18 analyst target with an asymmetry ratio of 3.66, but momentum failed its gate at 3.5 against 4.5. Suitability rationale | Momentum should recover above 4.5 and price should rise toward the $20.18 target. | →Stable |
| CounterThe engine finds no clear edge and a binary biotech industry; analyst coverage is light, so the upside rests on a few targets that may be stale. | ||
Quarterly revenue fell from $29.4M (March 2025) to $2.1M (March 2026) and $3.0M (June 2026), while net margin, ROE and ROA all score 0.0.
↓DeterioratingRevenue quarters
- Expectation
- Quarterly revenue should recover toward the $8.0M next-quarter estimate over the next 12 months.
CounterCollaboration revenue is milestone-based and lumpy, and revenue data shows large divergence between XBRL and yfinance (70% for the latest quarter), so the trend may be mismeasured.
Market cap $370M below $400M minimum keeps the stock outside the investable universe regardless of other scores.
↓DeterioratingBear case
- Expectation
- Market cap should rise above $400M for the stock to rejoin the investable universe.
CounterThe shortfall is only $30M, about 8%, so a modest price rise would qualify the stock; the screen threshold may be more arbitrary than informative.
High short interest of 24% and an elevated put/call ratio of 30.25 show strong bearish positioning against the stock.
↓DeterioratingKey risks
- Expectation
- Short interest should fall below 15% and put/call ratio should normalize if sentiment improves.
CounterThe engine notes the high short interest is justified, but heavily crowded shorts can also fuel a squeeze on any positive trial news.
Strong earnings: 3B/1M, with the latest quarter at EPS of -0.84 versus a -1.03 estimate (+18.1% surprise), showing losses narrower than analysts expect.
↓DeterioratingCatalyst breakdown
- Expectation
- EPS should beat estimates again at the 2026-11-09 report, keeping the beat count at 3 of the last 4 or better.
CounterBeating a loss estimate is not profitability; the company still loses roughly $0.84 per share each quarter, and one miss (-36.4%) was large.
After a 46% drawdown from the 52-week high, the stock trades 54.9% below its $20.18 analyst target with an asymmetry ratio of 3.66, but momentum failed its gate at 3.5 against 4.5.
→StableSuitability rationale
- Expectation
- Momentum should recover above 4.5 and price should rise toward the $20.18 target.
CounterThe engine finds no clear edge and a binary biotech industry; analyst coverage is light, so the upside rests on a few targets that may be stale.
Per-dimension breakdown
Quality
2.4/10data confidence 86%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.1 |
| Moat | 4.0 |
| Piotroski F | 3.3 |
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 8.0 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 6.0 |
| Volume | 0.0 |
- ▸Oversold in uptrend (RSI 30)
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.2 |
| Price target | 9.9 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (10.0) — signal dampened
- ▸Analyst upside: 82%
Insider
3.8/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 3.5 |
| notable moves | 3.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
3.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.2 |
| quality rank | 3.3 |
| growth rank | 0.5 |
Technical
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.6 |
| support resistance | 9.7 |
| 52w position | 0.6 |
| gap | 6.0 |
Risk (lower is worse)
2.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.1 |
| days to cover | 7.0 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 1.7 |
| debt equity | 9.5 |
- ▸High short interest justified: 24%
- ▸Elevated put/call: 30.25
- ▸High IV: 81%
- ▸Above max pain $2
Catalyst
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 5.8 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Market cap $369M below $400M minimum. Not in investable universe.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:MARKET_CAPPassed (7)
- ASYMMETRY:3.9>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:33d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:3.0<4.5
Warning (0)
none
Reward-to-Risk
3.88
Upside
+58.2%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -47% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The HOLD_IF_HOLDING verdict reflects the MOMENTUM gate's 3.0<4.5 outcome against Sentiment at 7.9 and asymmetric R:R of 3.88.
The strongest dimensions are Sentiment at 7.9, Technical at 6.2, and Value at 6.1; the weakest are Quality at 2.4, Risk (lower is worse) at 2.8, and Peer rank at 3.0. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 3.88 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Market Cap Below Universe Minimum
Trip ifMarket cap falls below $300M from current $370M.
- P2High Short Interest Put Skew
Trip ifShort interest rises above 30% from current 24%.
- P3Revenue Decline
Trip ifQuarterly revenue falls below $1M from the June 2026 level of $3.0M.
- P4Earnings Beat History
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.
- P5Deep Drawdown Analyst Upside
Trip ifMomentum score stays below 3.5 for 2 consecutive quarters.